重组溶葡萄球菌酶对奶牛乳房炎的疗效研究

以85头患乳房炎奶牛共104个乳区为研究对象,随机分为4组,每组26个,分别用重组溶葡萄球菌酶粉低（200U／乳区）、中（400U／乳区）、高（800U／乳区）三个剂量,对照组为青霉素G钠（160万IU／乳区）,每天早晚挤奶后乳池灌注给药,共4d,研究不同剂量重组溶葡萄球菌酶对奶牛乳房炎的治疗效果。试验结果显示,低、中、高剂量重组溶葡萄球菌酶均能有效清除感染乳区的链球菌、葡萄球菌、化脓隐秘杆菌等G^＋菌,大幅降低牛奶中的白细胞数,提高日产奶量。其中低剂量组对隐性乳房炎、临床型乳房炎的有效率和治愈率略优于青霉素G钠（P〉0．05）;中、高剂量对隐性乳房炎、临床型乳房炎的有效率和治愈率显著优于青霉素G钠（P〈0．05）;中、高剂量的疗效相当（P〉0．05）。重组溶葡萄球菌酶是一种很好的治疗奶牛隐性乳房炎和临床乳房炎备选药物。     

中草药添加剂对奶牛乳房炎及生产性能的影响

选择乳房炎奶牛16头，按照泌乳日、产奶量相近的原则随机分为对照组和试验组。对照组奶牛使用抗生素药物治疗，试验组奶牛在精料中添加中草药饲料添加剞代替抗生素治疗。结果表明：试验组奶牛乳房炎阳性率由41．48％降至3．13％，总有效率达到92．45％（P〈0．05）；并且使奶牛平均产奶量相对于对照组提高3．81kg／d（P〈0．05），乳脂率提高0．28％。     

博达（PortaSCC）法测试奶牛隐性乳房炎试验初报

利用美国近年研究并应用于实践的博达（P0rtaSCC）奶牛隐性乳房炎测试技术对太原某奶牛场的奶牛隐性乳房炎进行了监测，试验显示，博达（PortaSCC）隐性乳房炎测试技术方法简便快捷、测定数据准确，具有较大推广应用价值；此奶牛场奶牛隐性乳房炎头阳性率为54．29％（57／105），乳区阳性率为26．03％（107／411）；3胎及以上奶牛阳性率达到70．18％（40／57）并极显著高于1-2胎（35．42％，17／48）（P〈0．01）；奶牛个体混合乳样体细胞与个体乳区乳样体细胞平均数呈直线相关，差异极显著（r=0．7418，P〈0．01）。     

"乳炎必治注射液"对母畜乳房炎的疗效观察

乳炎必治注射液系纯中草药制剂。经临床大面积推广应用表明，乳炎必治试用于奶牛、奶山羊、猪、兔等家畜的乳房炎和产后疾病。共收治母猪73400头，其中治愈68300头，治愈率为93．10％；好转3300头，总有效率为97．55％。治疗母兔27600只，治愈25500只，治愈率为92．40％；好转1300只，有效率为97．10％；奶牛1200头，治愈1080头，治愈率为90．00％，好转94头，有效率为97．83％；奶山羊680只，治愈540只，治愈率为79．41％，好转11只，有效率为95．59％。同时对无名高热、产后综合症及仔畜黄、白痢亦有较好的效果。     

绿草素对奶牛乳房炎治疗的临床观察

奶牛乳房炎是长期以来困扰奶牛养殖的主要常见病,据有关报道我国奶牛乳房炎临床型发病率达２０％－６０％。通过此临床试验,结果表明绿草素对奶牛乳房炎的治愈率为９３．６％,总有效率９５．８３％,减轻率２．７８％,无效率为３．４７％,根据绿草素治疗特点,试验证明,绿草素与常用药青链霉素,氨苄青霉素等比较,奶牛乳房炎的治疗有其明显的优势。     

湖北地区奶牛乳房炎病原菌的分离鉴定与耐药性分析

本研究旨在分离鉴定湖北地区致奶牛乳房炎的病原菌，鉴定细菌的耐药特征．为奶牛乳房炎防治提供理论依据。从湖北两个主要奶牛小区的9个不同规模的奶牛场采集牛奶样本200份，经检测．其中3份为临床乳房炎样本，49份为隐性乳房炎。两地区隐性乳房炎的检出率分别为36．4％（20／55）与20％（29／145）。两地区乳房炎牛奶的细菌种类分布也各不同。其中武汉东西湖地区停乳链球菌的分离率最高，占33.3％（8／24）．而宜昌夷陵区以金黄色葡萄球菌分离率最高，占29％（9／31），其次为无乳链球菌，占25．8％（8／31）。从乳房炎牛奶中共分离到7种细菌共55株，其中金黄色葡萄球菌11株，表皮葡萄球菌10株，无乳链球菌10株，停乳链球菌14株，乳房链球菌2株，大肠埃希氏菌4株，克雷伯氏菌4株。分别对所有分离株进行12种药物的敏感性试验，结果表明所有菌株对先锋V、氧氟沙星均高度敏感．对临床常用的青霉素、链霉素具有较高的耐药性。     

苄青霉素治疗奶牛乳房炎的效果及在牛奶中残留规律的研究

本研究通过对临床确诊患乳房炎的76头奶牛,采用当地临床兽医常用的苄青霉素药物用4种不同的治疗方案进行治疗,有效率65%～86.3%(平均76.7%),治愈率65.0%￣72.7%(平均68.7%)。苄青霉素治疗奶牛乳房炎的效果较好,肌注苄青霉素联合静注土霉素的治愈率和有效率较低。通过药物残留检测,单独肌注苄青霉素、肌注苄青霉素联合静注土霉素的弃奶期4d(94h、95h)。单独乳房注入苄青霉素、乳注联合肌注普卡因青霉素的弃奶期3.5d(74h、76h)。     

应用生化黄腐酸对奶牛乳房炎和生产性能的影响

通过32头泌乳奶牛饲喂生化黄腐酸的对比试验。结果表明,生化黄腐酸对奶牛乳房炎、隐性乳房炎有效率达100％,治愈率达80％;试验组比对照组产奶量提高13．84％（P〈0．05）;校正体重后试验组比对照组产奶量提高14．94％（P〈0．05）;提高饲料转化率13．79％（P〈0．05）;每头奶牛每年增加的经济效益=产奶量提高效益＋牛奶级别提高效益＋防治乳房炎、隐性乳房炎减少的牛奶损失=881．45元＋400元＋377．86元=1659．31元,增收效益显著。     

热毒通解对高烧高热性疾病的临床疗效观察

高烧高热性疾病是由细菌、病毒引起的一种常见症状，此症顽固多发，严重困扰养殖户。为此，我们以成都双流某猪场自然发病病例为病理模型，以注射用水、安乃近分别为阴、阳性对照组，观察热毒通解对典型的高热性疾病的疗效。结果表明：热毒通解对猪感冒发烧的总有效率为100％(30／30)，治愈率为93．3％(28／30)；蒸馏水的总有效率为20％(4／20)；30％安乃近的总有效率为90．0％(18／20)，治愈率为10．0％(2／20)。     

博达 （PortaSCC ）法测试奶牛隐性乳房炎试验报告

利用PortaSCC奶牛隐性乳房炎测试技术对太原和朔州两地的奶牛隐性乳房炎进行了监测。结果显示,PortaSC妒隐性乳房炎测试技术方法简便·陕捷、测定数据准确,具有较大的应用价值;奶牛隐性乳房炎头阳性率为55．5％（111／2O0）,乳区阳性率为26．34％（196／744）;3胎及以上奶牛乳房炎阳性率达到70．18％（40／57）并显著高于1-2胎35．42％（17／48）（P〈0．01）;奶牛个体混合乳样体细胞与个体乳区乳样体细胞平均数呈直线相关,差异极显著（r=0.7418,t〉t0.01,P〈0．01）。     

公英翘芦散治疗亚临床型奶牛乳房炎的效果研究

本研究旨在初步考察公英翘芦散对亚临床奶牛乳房炎的临床治疗效果。试验选取78头发病牛，其中38头牛为散发，用公英翘芦散治疗；40头牛集中对比治疗，随机分成2组，每组20头，分别用公英翘芦散和公英散进行治疗。用加州乳房炎检验（California mastitis trial，CMT）法检测公英翘芦散治疗后乳区患病状态并判定其治疗效果；用体细胞计数（somatic cell count，SCC）法检测公英翘芦散和公英散治疗后牛奶体细胞数并判定其治疗效果。结果显示，公英翘芦散给药7 d后，患病乳区由75个减少到28个，治疗效果非常显著，治愈率达到62.67%，有效率达到90.67%。与治疗前相比，公英翘芦散和公英散用药1 d后体细胞数均极显著降低（P<0.01），且公英翘芦散组SCC下降幅度明显超过公英散组。公英翘芦散组在给药2 d后体细胞数显著低于公英散组（P<0.05），给药3 d之后均极显著低于公英散组（P<0.01）。用药7 d后，公英翘芦散组治愈率可达68.29%，而公英散组治愈率只达到20.00%，差异极显著（P<0.01）；公英翘芦散组有效率可达97.56%，而公英散组有效率为67.50%，差异极显著（P<0.01），说明公英翘芦散的治疗效果极显著优于公英散（P<0.01）。以上结果说明，公英翘芦散可以作为治疗亚临床奶牛乳房炎的有效药物，为奶牛乳房炎药物的开发提供参考。     

Efficacy of extended intramammary ceftiofur therapy against mild to moderate clinical mastitis in Holstein dairy cows: A randomized clinical trial

Few studies have investigated the efficacy of extended ceftiofur therapy and none have focused on extended therapy for naturally occurring clinical mastitis. The objective of this study was to compare the efficacy of extended intramammary ceftiofur therapy of 8 d duration with a standard 2-day regimen for the treatment of naturally occurring mild to moderate clinical mastitis in lactating dairy cows. Holstein cows from 22 dairy herds (n = 241) were randomly allocated to the 2 treatment groups. For each case of mastitis, 125 mg of ceftiofur hydrochloride was administered intramammary once a day for 2 or 8 d. Clinical cure, 21 d after the last treatment, was 89% (98/110) in each group. Bacteriological cure 21 d after the last treatment for the 2- and 8-day regimens were 32% (15/47) and 61% (25/41), respectively, for all bacteria (P = 0.007), 64% (9/14) and 82% (9/11), respectively, for streptococci (P = 0.50), and 0% (0/20) and 47% (9/19), respectively, for Staphylococcus aureus (P = 0.0004). There were no statistical differences between groups for new intramammary infections. Overall, ceftiofur extended therapy increased cure when compared to a 2-day regimen for the treatment of naturally occurring mild to moderate clinical mastitis in lactating dairy cows.     

Antibiotic resistance of staphylococci from humans, food and different animal species according to data of the Hungarian resistance monitoring system in 2001

Based on data of the Hungarian resistance monitoring system the antibiotic resistance of Staphylococcus strains of human and animal origin was studied. No methicillin-resistant staphylococci harbouring mecA gene were isolated from animals in 2001. Penicillin resistance, mediated by penicillinase production, was the most frequent among Staphylococcus aureus strains isolated from humans (96%), from bovine mastitis (55%), from foods (45%) and from dogs. In staphylococci isolated from animals low resistance percentages to aminoglycosides (0-2%), fluoroquinolones (0.5-3%) and sulphonamides (0.5-4%) were found but in strains isolated humans these figures were higher (1-14%, 5-18% and 3-31%, respectively). The most frequent antibiotic resistance profiles of strains isolated from animals and food were penicillin/tetracycline, penicillin/lincomycin and penicillin/lincomycin/tetracycline. Penicillin/tetracycline resistance was exhibited by strains from mastitis (3), samples from the meat industry (31), poultry flocks (1), poultry industry (1), noodle (1) and horses (2). Penicillin/lincomycin resistance was found in 10 Staphylococcus strains from mastitis, 1 from the dairy industry, 1 from the meat industry and 6 from dogs. Isolates from mastitis (2), from the dairy industry (2), from pigs (1), from the meat industry (1) and from poultry (1) harboured penicillin/lincomycin/tetracycline resistance pattern. Multiresistant strains were usually isolated only from one and sometimes from two animal species; therefore, the spread of defined resistant strains (clones) among different animal species could not be demonstrated. These results also suggest that the transfer of antibiotic resistance of S. aureus from animals to humans probably occurs less frequently than is generally assumed.     

Current data on antibiotic resistance of the most important bovine mastitis pathogens in Switzerland

100 strains of Staphylococcus aureus (S. aureus), 100 strains of coagulase-negative staphylococci (CNS), 100 strains of Streptococcus spp. and 100 strains of Escherichia coli (E. coli), isolated from bovine mastitis milk samples between November 2002 and April 2003, were tested for their sensitivity to various antibiotics by means of the agar diffusion method. The antibiotics were chosen on the basis of their licenses for intramammary application in Switzerland (www.vetpharm.unizh.ch). 91% of the S. aureus strains were sensitive to all the antibiotics tested. Only 9% of the strains were resistant to Penicillin G and 7% to Ampicillin. 53% of the CNS strains were sensitive to all the antibiotics tested. 31% exhibited resistance to Penicillin G, 26% to Ampicillin, 16% to Cloxacillin and 14% to Lincomycin. 30% of the Streptococcus spp. strains were sensitive to all the antibiotics tested. 4% were resistant to Penicillin G, 4% to Amoxicillin/clavulanic acid, 1% to Cefoperazone, 2% to Cefquinome, 35% to Neomycin, 22% to Gentamicin, 61% to Kanamy-cin and 11% to Lincomycin. 43% of the strains showed multiple resistance. 79% of the E. coli strains were sensitive to all the antibiotics tested. 20% exhibited resistance to Ampicillin, 9% to Neomycin and 10% to Kanamycin. A comparison of the own results with data of other authors in Switzerland shows no important changes in the resistance situation during the last 20 years. With the exception of two strains (Streptococcus spp.), all tested isolates were sensible against Cefquinome.     

Clinical and bacteriological response to treatment of clinical mastitis with one of three intramammary antibiotics

AIM: To compare the proportions of clinical and bacteriological cure of glands of dairy cows diagnosed with clinical mastitis, following treatment with one of three different intramammary antibiotic preparations. METHODS: Cows from dairy cow herds (n=28) across New Zealand which were diagnosed with clinical mastitis in one or more glands at any stage of lactation were randomly assigned at the cow level within sequentially presented groups of three animals to be treated with one of three intramammary antibiotics. The treatments were 1 g procaine penicillin, 0.25 g cefuroxime, and a combination of 1 g procaine penicillin and 0.5 g dihydrostreptomycin (DHS). All treatments were infused on three occasions at 12-hourly intervals. Duplicate milk samples were collected for bacteriology before initial treatment, and 21-42 days later. Logistic regression or generalised linear mixed models were used to analyse the proportion of cows or quarters retreated for mastitis within 30 days of initial treatment ('clinical treatment failure'), and the proportion of glands from which bacteria were isolated initially but from which the same bacterial species was not re-isolated ('bacteriological cure'). RESULTS: The annual herd average cumulative incidence rate of clinical mastitis was 12.7 cases/100 cows. The incidence rate was higher in young (2-year-old) and old (> or = 9-year-old) cows relative to 3- and 4-year-old cows, and was higher in Friesian than Jersey or crossbred cows. Streptococcus uberis was the pathogen most commonly isolated, and its relative prevalence declined with time postpartum. Cows treated with cefuroxime were more likely (p<0.01) to be re-treated for clinical mastitis in the 30 days after initial treatment than cows treated with procaine penicillin or procaine penicillin and DHS. Bacteriological cure occurred in 74% of treated glands and there was no difference in the proportion of cures among the treatments (p=0.4). The proportion of cures was lower when treatment occurred 28-72 days after calving (p<0.01) and if a major pathogen was isolated (p<0.001). CONCLUSIONS AND CLINICAL RELEVANCE: There was no benefit in terms of clinical or bacteriological cure rate in treating clinical mastitis cases with the combination of procaine penicillin and DHS compared to treatment with procaine penicillin alone. The proportion of clinical mastitis cases re-treated differed among herds, and more cows treated with cefuroxime were retreated within 30 days of initial treatment. However, the bacteriological cure proportion was the same among the treatments. Cure proportions were lower in cows from which major mastitis pathogens were isolated and when treatment commenced 28-72 days after calving.     

青海省部分规模化奶牛场乳房炎主要病原菌调查分析

为了初步摸清青海省部分规模化奶牛场奶牛乳房炎的发病情况,本研究采集了青海省5个规模化奶牛场共142份样品,进行细菌的分离鉴定、生化实验及耐药性检测。发现在5个规模化奶牛场中都有不同程度的乳房炎发生。鉴定结果显示,在142份样品中共检出大肠杆菌20株,检出率为14.08%(20/142);金黄色葡萄球菌6株,检出率为4.23%(6/142);链球菌2株,检出率为1.41%(2/142)。耐药性检测结果显示,大肠杆菌对氟苯尼考高度敏感,对头孢他啶、丁胺卡那比较敏感,对青霉素、链霉素等其他药物耐药。金黄色葡萄球菌对万古霉素、阿莫西林、氨苄西林、头孢他啶较敏感,对其他药物耐药。链球菌对阿莫西林、氨苄西林敏感,对其他药物耐药。     

A comparative efficacy trial between cefuroxime and cloxacillin as intramammary treatments for clinical mastitis in lactating cows on commercial dairy farms

AIMS: To assess the efficacy of a commercial intramammary preparation containing cefuroxime as a treatment for clinical mastitis in lactating dairy cows. METHODS: Clinical mastitis cases (n=440) were identified during early to mid lactation on 36 seasonally-calving commercial dairy herds in south-western Victoria, Australia, that ranged in size from 140 to 550 cows. A milk sample for bacterial culture was collected from each affected quarter prior to treatment. Cases were treated using a commercial intramammary antibiotic product containing either 250 mg cefuroxime or 200 mg cloxacillin, according to the manufacturer's recommendations, and the recommended milk with-holding period was observed. The assessment of clinical cure of each case was made by the farm owner/manager at the end of the milk with-holding period. Post-treatment milk samples were taken from clinically cured quarters at each of three consecutive milkings, commencing 7 days after the end of the milk with-holding period and submitted for bacterial culture. RESULTS: Pathogenic bacteria were isolated from 252/416 (60.6%) pre-treatment milk samples submitted from eligible cases. Streptococcus uberis was the most frequent isolate, being cultured from 31.7% of cases. Staphylococcus aureus was isolated from 18.3% of pre-treatment samples, and Esherichia coli from 7.0%. The clinical cure rate for all eligible cases was 81.7%. There was no significant difference in clinical cure rates between cases treated with cefuroxime (186/225=82.7%) and cases treated with cloxacillin (154/191=80.6%). The trial had 80% power to detect a significant difference if the actual cure rates differed by at least 12.6%. There was a superior clinical response rate (p=0.04) for mastitis cases from which E. coli was isolated that were treated with cefuroxime (18/19=95%) compared with cloxacillin 6/10=60%), but case numbers were low (n=29). The overall bacteriological cure rate for the trial was 70% (69/98 cases assessed). There was no significant difference (p=0.27) in bacteriological cure rate between cases treated with cefuroxime (42/56=75%) and cases treated with cloxacillin (27/42=64%). CONCLUSIONS: This trial demonstrated that cefuroxime was an effective intramammary treatment for clinical mastitis and had similar clinical and bacteriological cure rates to cloxacillin, an accepted industry-standard product. Activity against Gram-negative and Gram-positive bacteria was demonstrated for cefuroxime which, along with the economic benefits of less discarded milk compared with other antibiotic preparations, indicated that cefuroxime is likely to be an appropriate intramammary antibiotic for the treatment of clinical mastitis in commercial dairy herds during early to mid lactation in Victoria, Australia.     

中药复方灌注剂对奶牛乳房炎的防治效果及免疫增强作用

选取临床型、隐性型和健康型荷斯坦奶牛共80头,用于中药复方灌注剂对奶牛乳房炎的防治及免疫试验,对治疗前后乳中体细胞数(SCC)、乳清中白蛋白(SA)、乳酸脱氢酶(LDH)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、淋巴细胞刺激指数(SI)、嗜中性粒细胞吞噬率和使用前后干奶期乳房炎的发病率进行了研究。结果表明,中药复方灌注剂和抗生素对隐性乳房炎的治愈率分别为94.44%和88.24%,有效率均为100%;对临床型乳房炎的治愈率分别为86.67%和76.92%,有效率为93.33%和84.62%;对干奶期乳房炎的预防效果分别为88.89%和94.12%,而生理盐水对照组发病率高达45.45%。中药复方灌注剂可以极显著降低患病奶牛乳中SCC、SA、LDH、ALT、AST水平(P＜0.01),提高SI和嗜中性粒细胞吞噬率(P＜0.01)。试验证实了中药复方灌注剂对奶牛乳房炎有较好的防治效果,能够修复奶牛受损的乳腺上皮细胞,降低受损细胞产生的酶含量和血乳的渗透性,提高患病奶牛机体的免疫机能。     

Intramammary treatment of clinical mastitis of dairy cows with a combination of lincomycin and neomycin, or penicillin and dihydrostreptomycin

AIM: To compare clinical and bacteriological cure rates of clinical mastitis following treatment with intramammary preparations containing either lincomycin and neomycin or penicillin and dihydrostreptomycin. METHODS: Cases of clinical mastitis were sourced from four seasonal-calving dairy herds in the central Waikato region of New Zealand during the first 120 days of lactation. Affected quarters were infused three times at 12 h intervals with either 333 mg lincomycin plus 100 mg neomycin (lin/neo; 197 glands),or 1,000 mg penicillin plus 500 mg dihydrostreptomycin (pen/DHS; 207 glands). Milk samples were collected for bacteriology from each quarter immediately before and approximately 21 days after initiation of treatment. Additionally, a composite milk sample from each cow was collected, on average, 54 days after enrolment for assessment of milk yield, composition and somatic cell count (SCC). The probability of bacterial cure was initially analysed using Chi-squared analysis, and factors that were associated (p<0.2) were offered to a reverse stepwise logistic regression model. Continuous variables (e.g. milk solids production and log10 SCC) were analysed using general linear models. RESULTS: A total of 404 quarters diagnosed with clinical mastitis, from 282 cows in the first 120 days of lactation, were included. Streptococcus uberis, coagulase-negative staphylococci and Staphylococcus aureus were isolated from 56.5%, 18.8% and 10.0% of the bacteriologically positive quarters. There was no difference in the bacteriological cure rate (76.7% vs 76.7%, OR=0.94; p>0.8), the log10 SCC (2.1, SE 0.1, vs 2.0, SE 0.1; p>0.3) or milk production (1.2, SE 0.1, vs 1.2, SE 0.1, kg milksolids/cow/day; p>0.7) between lin/neo vs pen/DHS treatments, respectively. However, the proportion of cows re-treated following initial treatment was higher for the lin/neo compared to pen/DHS-treated group (16.3% vs 5.2%, OR=3.46; p<0.05). CONCLUSIONS: No difference in bacteriological cure rate, milk production or SCC was evident between lin/neo and pen/DHS intramammary treatments for clinical mastitis in dairy cows during the first 120 days of lactation. KEYWORDS: Dairy cow, mastitis, intramammary, antibiotic, treatment, somatic cell count.     

复方阿莫西林乳房注入剂治疗临床型奶牛乳房炎的疗效观察

为评价复方阿莫西林乳房注入剂治疗临床型奶牛乳房炎的疗效,在北京某牛场选择25头(48个乳区)临床型乳房炎患牛进行疗效观察。将临床型乳房炎患牛随机分为受试药物组(25个乳区)和对照药物组(23个乳区)。受试药物组患病乳区灌注复方阿莫西林乳房注入剂,对照药物组则灌注速诺LC。采用临床学与细菌学治愈率相结合的方法进行药效学评价。复方阿莫西林乳房注入剂治疗临床型乳房炎的临床学治愈率为68.0%,细菌学治愈率为83.3%,而速诺LC治疗组分别为69.6%、81.8%,两者治疗效果无显著性差异(P>0.05)。结果表明,复方阿莫西林乳房注入剂对临床型乳房炎具有较好的治疗效果。